Finanzen von LENZ Therapeutics Inc (LENZ)LENZLENZ Therapeutics Inc

Evaluating the bottom line, LENZ Therapeutics, Inc. maintains a gross margin of 86.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -972.75%, while the net margin is -915.16%. These profitability ratios, combined with a Return on Equity (ROE) of -72.69%, provide a clear picture of how effectively LENZ converts its operational activities into shareholder value.

In the context of the broader market, LENZ competes directly with industry leaders such as RTSN and GNLX. With a market capitalization of $94.57M, it holds a leading position in the sector. When comparing efficiency, LENZ's gross margin of 86.58% stands against RTSN's N/A and GNLX's N/A. Such benchmarking helps identify whether LENZ Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

LENZ reported a gross margin of 94.90% in Q2 2026, indicating strong profitability potential as sales grow. Despite this, the company has faced substantial net losses, with a net income of -30,969,000 USD in Q3 2026, reflecting ongoing challenges in achieving profitability.